162 related articles for article (PubMed ID: 32188713)
1. Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome.
Puhr HC; Pablik E; Berghoff AS; Jomrich G; Schoppmann SF; Preusser M; Ilhan-Mutlu A
ESMO Open; 2020 Mar; 5(2):. PubMed ID: 32188713
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer.
Crumley AB; McMillan DC; McKernan M; McDonald AC; Stuart RC
Br J Cancer; 2006 Mar; 94(5):637-41. PubMed ID: 16479253
[TBL] [Abstract][Full Text] [Related]
3. Development of an alarm symptom-based risk prediction score for localized oesophagogastric adenocarcinoma (VIOLA score).
Puhr HC; Puhr R; Kuchling DA; Jahic L; Takats J; Reiter TJ; Paireder M; Jomrich G; Schoppmann SF; Berghoff AS; Preusser M; Ilhan-Mutlu A
ESMO Open; 2022 Aug; 7(4):100519. PubMed ID: 35759854
[TBL] [Abstract][Full Text] [Related]
4. Role of symptoms in diagnosis and outcome of gastric cancer.
Maconi G; Manes G; Porro GB
World J Gastroenterol; 2008 Feb; 14(8):1149-55. PubMed ID: 18300338
[TBL] [Abstract][Full Text] [Related]
5. Identifying patients with suspected gastro-oesophageal cancer in primary care: derivation and validation of an algorithm.
Hippisley-Cox J; Coupland C
Br J Gen Pract; 2011 Nov; 61(592):e707-14. PubMed ID: 22054334
[TBL] [Abstract][Full Text] [Related]
6. Use of alarm symptoms to select dyspeptics for endoscopy causes patients with curable esophagogastric cancer to be overlooked.
Bowrey DJ; Griffin SM; Wayman J; Karat D; Hayes N; Raimes SA
Surg Endosc; 2006 Nov; 20(11):1725-8. PubMed ID: 17024539
[TBL] [Abstract][Full Text] [Related]
7. Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.
Fareed KR; Al-Attar A; Soomro IN; Kaye PV; Patel J; Lobo DN; Parsons SL; Madhusudan S
Br J Cancer; 2010 May; 102(11):1600-7. PubMed ID: 20461087
[TBL] [Abstract][Full Text] [Related]
8. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.
Van Cutsem E; di Bartolomeo M; Smyth E; Chau I; Park H; Siena S; Lonardi S; Wainberg ZA; Ajani J; Chao J; Janjigian Y; Qin A; Singh J; Barlaskar F; Kawaguchi Y; Ku G
Lancet Oncol; 2023 Jul; 24(7):744-756. PubMed ID: 37329891
[TBL] [Abstract][Full Text] [Related]
10. Identifying patients with undetected gastro-oesophageal cancer in primary care: External validation of QCancer® (Gastro-Oesophageal).
Collins GS; Altman DG
Eur J Cancer; 2013 Mar; 49(5):1040-8. PubMed ID: 23159533
[TBL] [Abstract][Full Text] [Related]
11. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1,128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms.
Voutilainen M; Sipponen P; Mecklin JP; Juhola M; Färkkilä M
Digestion; 2000; 61(1):6-13. PubMed ID: 10671769
[TBL] [Abstract][Full Text] [Related]
12. Evaluating a computer aid for assessing stomach symptoms (ECASS): study protocol for a randomised controlled trial.
Moore HJ; Nixon C; Tariq A; Emery J; Hamilton W; Hoare Z; Kershenbaum A; Neal RD; Ukoumunne OC; Usher-Smith J; Walter FM; Whyte S; Rubin G
Trials; 2016 Apr; 17():184. PubMed ID: 27044367
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
[TBL] [Abstract][Full Text] [Related]
14. Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery.
Vošmik M; Laco J; Sirák I; Dvořák J; Lochman P; Hodek M; Malá P; Rejchrt S; Repák R; Leško M; Ferko A; Ryška A; Melichar B; Petera J
Pathol Oncol Res; 2018 Apr; 24(2):373-383. PubMed ID: 28550507
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Shitara K; Özgüroğlu M; Bang YJ; Di Bartolomeo M; Mandalà M; Ryu MH; Fornaro L; Olesiński T; Caglevic C; Chung HC; Muro K; Goekkurt E; Mansoor W; McDermott RS; Shacham-Shmueli E; Chen X; Mayo C; Kang SP; Ohtsu A; Fuchs CS;
Lancet; 2018 Jul; 392(10142):123-133. PubMed ID: 29880231
[TBL] [Abstract][Full Text] [Related]
16. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K; Lordick F; Bang YJ; Enzinger P; Ilson D; Shah MA; Van Cutsem E; Xu RH; Aprile G; Xu J; Chao J; Pazo-Cid R; Kang YK; Yang J; Moran D; Bhattacharya P; Arozullah A; Park JW; Oh M; Ajani JA
Lancet; 2023 May; 401(10389):1655-1668. PubMed ID: 37068504
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pre-treatment clinical prognostic factors in patients with gastro-oesophageal cancer and proposal of a new staging system.
Crumley AB; Stuart RC; McKernan M; Going JJ; Shearer CJ; McMillan DC
J Gastrointest Surg; 2010 May; 14(5):781-7. PubMed ID: 20148314
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi T; Shitara K; Naito Y; Shimomura A; Fujiwara Y; Yonemori K; Shimizu C; Shimoi T; Kuboki Y; Matsubara N; Kitano A; Jikoh T; Lee C; Fujisaki Y; Ogitani Y; Yver A; Tamura K
Lancet Oncol; 2017 Nov; 18(11):1512-1522. PubMed ID: 29037983
[TBL] [Abstract][Full Text] [Related]
19. Does endoscopy diagnose early gastrointestinal cancer in patients with uncomplicated dyspepsia?
Sundar N; Muraleedharan V; Pandit J; Green JT; Crimmins R; Swift GL
Postgrad Med J; 2006 Jan; 82(963):52-4. PubMed ID: 16397081
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
